Genetically engineered Newcastle disease virus for prostate cancer: a magic bullet or a misfit

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA. Cancer J. Clin. 59(4), 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Medicine IO. Initial national priorities for comparative effectiveness research. National Academies Press, Washington, DC, USA, 1–253 (2009).
   Google Scholar
• Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23(32), 8253–8261 (2005).
   PubMed Web of Science ®Google Scholar
• Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol. Clin. North Am. 18(1), 15–24 (1991).
   PubMed Web of Science ®Google Scholar
• Sinkovics JG. Progressive development of viral therapy of human cancers; a personal narrative account. In: Viral Therapy of Human Cancers. Sinkovics JG, Horvath JC (Eds.). Marcel Dekker, New York, NY, USA, 1–148 (2005).
   Google Scholar
• Wheelock EF, Dingle JH. Observations on the repeated administration of viruses to a patient with acute leukemia: a preliminary report. N. Engl. J. Med. 271, 645–651 (1964).
   PubMed Web of Science ®Google Scholar
• Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer 18, 863–868 (1965).
   PubMed Web of Science ®Google Scholar
• Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 7(3), 347–367 (2012).
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Burke J, Jonker D et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477(7362), 99–102 (2011).
   PubMed Web of Science ®Google Scholar
• Echchgadda I, Kota S, DeLa Cruz I et al. Anticancer oncolytic activity of respiratory syncytial virus. Cancer Gene Ther. 16(12), 923–935 (2009).
   PubMedGoogle Scholar
• Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int. J. Cancer 124(10), 2478–2487 (2009).
   PubMed Web of Science ®Google Scholar
• Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 69(10), 1128–1141 (2009).
   PubMed Web of Science ®Google Scholar
• Carey BL, Ahmed M, Puckett S, Lyles DS. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J. Virol. 82(24), 12104–12115 (2008).
   PubMed Web of Science ®Google Scholar
• Krishnamurthy S, Huang Z, Samal SK. Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 278(1), 168–182 (2000).
   PubMed Web of Science ®Google Scholar
• Aghi M, Martuza RL. Oncolytic viral therapies – the clinical experience. Oncogene 24(52), 7802–7816 (2005).
   PubMed Web of Science ®Google Scholar
• Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett. 172(1), 27–36 (2001).
   PubMed Web of Science ®Google Scholar
• Elankumaran S, Rockemann D, Samal SK. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J. Virol. 80(15), 7522–7534 (2006).
   PubMed Web of Science ®Google Scholar
• Biswas M, Kumar SR, Allen A et al. Cell-type-specific innate immune response to oncolytic Newcastle disease virus. Viral Immunol. 25(4), 268–276 (2012).
   PubMedGoogle Scholar
• Elankumaran S, Chavan V, Qiao D et al. Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J. Virol. 84(8), 3835–3844 (2010).
   PubMed Web of Science ®Google Scholar
• Biswas M, Johnson JB, Kumar SR, Parks GD, Elankumaran S. Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. J. Virol. 86(23), 12708–12716 (2012).
   PubMed Web of Science ®Google Scholar
• Shobana R, Samal SK, Elankumaran S. Prostate-specific antigen-retargeted recombinant Newcastle disease virus for prostate cancer virotherapy. J. Virol. 87(7), 3792–3800 (2013).
   PubMed Web of Science ®Google Scholar
• Rajput R, Sehgal A. Endocrine manipulations in cancer prostate: a review. Indian J. Endocrinol. Metab. 16(Suppl. 2), S199–S204 (2012).
   Google Scholar
• Palmberg C, Koivisto P, Visakorpi T, Tammela TL. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur. Urol. 36(3), 191–196 (1999).
   PubMed Web of Science ®Google Scholar
• Oh WK, Halabi S, Kelly WK et al.; Cancer and Leukemia Group B 99813. A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 98(12), 2592–2598 (2003).
   PubMed Web of Science ®Google Scholar
• Cooperberg MR. Thwarting high-risk prostate cancer: the right treatments for the right patients. Eur. Urol. 61(6), 1107–1109 (2012).
   PubMedGoogle Scholar
• Warde P, Mason M, Ding K et al.; NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, Phase 3 trial. Lancet 378(9809), 2104–2111 (2011).
   PubMed Web of Science ®Google Scholar
• Bourke L, Kirkbride P, Hooper R, Rosario AJ, Chico TJ, Rosario DJ. Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost–effectiveness? Br. J. Cancer 108(1), 9–13 (2013).
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J. Natl Cancer Inst. 102(1), 39–46 (2010).
   PubMed Web of Science ®Google Scholar
• Thompson CB, Shepard HM, O’Connor PM et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol. Cancer Ther. 9(11), 3052–3064 (2010).
   PubMed Web of Science ®Google Scholar
• Song KY, Wong J, Gonzalez L, Sheng G, Zamarin D, Fong Y. Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. J. Mol. Med. 88(6), 589–596 (2010).
   PubMed Web of Science ®Google Scholar